TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00495248

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group intervention inspired by Lifestyle Redesign
Description: Group intervention inspired by Lifestyle Redesign

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group intervention inspired by Lifestyle redesign
Description: Lifestyle programme once a week for two hours over an intervention period of 9 months
Study: NCT02714972

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperglycemia Minimization Algorithm
Description: The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
Study: NCT00201513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Isolated Transversus abdominis (TrA) exercise
Description: Eight weeks Isolated Transversus abdominis (TrA) exercise(low load) program; Isolated TrA control through biofeedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sling exercise
Description: Eight weeks sling(high load) exercise program; Isolated TrA control through biofeedback

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: group exercise
Description: Eight weeks non-specific group exercise program; Isolated TrA control through biofeedback
Study: NCT03277339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Deroxat® (20 mg/day) 3 week; can be increase on week 2 until 50 mg.

Intervention type: OTHER
Group type: OTHER
Intervention: Thermal cure
Description: Thermal cure is realized for 3 weeks
Study: NCT02695420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Omecamtiv Mecarbil
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Omecamtiv Mecarbil
Description: oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 25 mg Omecamtiv Mecarbil
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 37.5 mg Omecamtiv Mecarbil
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg Omecamtiv Mecarbil
Description: oral tablet
Study: NCT02773576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone implant
Study: NCT00888719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CWP-0403 100mg
Description: 100mg/tablet, Twice a day, 1 tablet at a time for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Tablet not containing CWP-0403 and indistinguishable from CWP-0403 50mg, 100mg tablets.~Twice a day, 1 tablet at a time for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CWP-0403 50mg
Description: 50mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
Study: NCT00092443

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq™, rotavirus vaccine, live, oral, pentavalent
Description: Three doses of RotaTeq™ administered 28 to 70 days apart.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo matching RotaTeq™
Description: Placebo matching RotaTeq™ administered 28 to 70 days apart.
Study: NCT01439828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcystein
Description: Visit 1: Consent signed. Blood and urine analysis. Questionnaires assessing cannabis and tobacco's craving.N-acetylcystein and placebo doses will be increased if craving decreases \<25% compared to previous visit.The doses start at 200 mg x 4/24h to 800 mg x 4/24h.Visit 2 to 5: Medication safety and cannabis craving and withdrawal assessment during 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-acetylcystein
Description: Visit 1: Consent signed. Blood and urine analysis. Questionnaires assessing cannabis and tobacco's craving.N-acetylcystein and placebo doses will be increased if craving decreases \<25% compared to previous visit.The doses start at 200 mg x 4/24h to 800 mg x 4/24h.Visit 2 to 5: Medication safety and cannabis craving and withdrawal assessment during 4 weeks.
Study: NCT00707941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Children ≤12 years: Suspension by Weight (Kg) as follows: Dose X 5 days Volume (ml) \< 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows:~1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Children ≤12 years: Suspension by Weight (Kg) as follows: Dose X 5 days Volume (ml) \< 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows:~1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children \< 12 years, suspension by weight (kg) as follows: Dose X 5 days Volume (ml) \< 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows 1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children \< 12 years, suspension by weight (kg) as follows: Dose X 5 days Volume (ml) \< 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows 1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25
Study: NCT01755819

Intervention type: DEVICE
Group type: OTHER
Intervention: Biocomposite interference screw

Intervention type: DEVICE
Group type: OTHER
Intervention: Extracortical ACL Tightrope fixation
Study: NCT03174600

Intervention type: OTHER
Intervention: Questionnaire
Description: The patients were questioned using the Danish Prostatic Symptom Score (DAN-PSS), and evaluated using modified Barthel index, incontinence quality of life questionnaire (I-QOL), and the Mini-Mental Test (MMT) on the 1st, 3rd and 6th months.
Study: NCT04775628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inferior glide humerus in GH joint
Description: Supine inferior glide GH joint
Study: NCT04655989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBB-EXA ES Hemodialysis System
Description: The DBB-EXA ES Hemodialysis Delivery System is intended to support an optional online priming, rinseback and emergency bolus features. The appropriate priming of the hollow fiber dialyzer and blood tubing lines removes debris and air prior to device use, as well as ensuring proper rinseback.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBB-EXA ES Hemodialysis System
Description: The DBB-EXA ES Hemodialysis Delivery System is intended to support an optional online priming, rinseback and emergency bolus features. The appropriate priming of the hollow fiber dialyzer and blood tubing lines removes debris and air prior to device use, as well as ensuring proper rinseback.

Intervention type: DEVICE
Group type: OTHER
Intervention: DBB-EXA ES Hemodialysis System
Description: The DBB-EXA ES Hemodialysis Delivery System is intended to support an optional online priming, rinseback and emergency bolus features. The appropriate priming of the hollow fiber dialyzer and blood tubing lines removes debris and air prior to device use, as well as ensuring proper rinseback.
Study: NCT03500224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-TAK-954
Description: \[14C\]-TAK-954 intravenous infusion.
Study: NCT00268853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPOP-R
Description: Cyclophosphamide 750 mg/m2, pixantrone 150 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP-R
Description: Cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
Study: NCT00713297

Intervention type: BEHAVIORAL
Intervention: satisfaction questionnaire
Description: Satisfaction questionnaire
Study: NCT01885585

Intervention type: DRUG
Intervention: Apixaban
Study: NCT01586130

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise in eccentric or concentric mode
Description: In this therapeutic field, isokinetic exercises seem to have a better efficiency than other, more frequently used, kinds of exercises such as isometric or isotonic exercises.

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise in eccentric or concentric mode
Description: In this therapeutic field, isokinetic exercises seem to have a better efficiency than other, more frequently used, kinds of exercises such as isometric or isotonic exercises.
Study: NCT01500720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Cabazitaxel 25 milligram per square meter (mg/m\^2) intravenously (IV) on Day 1 every 3 weeks (21-day cycle) until unacceptable toxicity, disease progression or withdrawal consent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan 1.5 mg/m\^2 IV on Day 1 to Day 5 every 3 weeks (21-Day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
Study: NCT02633020

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 714
Description: Administered via a 120-minute IV infusion for a total of 7 times over 10 weeks.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via a 120-minute IV infusion for a total of 7 times over 10 weeks.
Study: NCT03433040

Intervention type: DRUG
Group type: OTHER
Intervention: 17-Hydroxyprogesterone Capronate
Description: 17-Hydroxyprogesterone Capronate 250mg versus 500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-Hydroxyprogesterone Capronate
Description: 17-Hydroxyprogesterone Capronate 250mg versus 500mg

Intervention type: DRUG
Group type: OTHER
Intervention: 17-Hydroxyprogesterone Capronate
Description: 17-Hydroxyprogesterone Capronate 250mg versus 500mg
Study: NCT00249899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and stable statin therapy
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and stable statin therapy for up to 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stable statin therapy
Description: Lapaquistat acetate placebo-matching, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
Study: NCT01229293

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Articular Surface Replacement (ASR)
Description: Articular surface replacement, DePuy, posterolateral approach used

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Total Hip Arthroplasty (THA)
Description: Device: Biomet 28mm
Study: NCT00221117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuroprosthesis-FES Therapy
Description: The Compex Motion neuroprostesis, developed by Drs. R. Popovic and Thierry Keller,and company Compex SA, ia a flexible device designed to improve grasping function in both SCI and stroke patients.This multi-channel surface stimulation system for grasping provides both palmar and lateral grasp , and holds a number of advantages over the other existing neuroprostheses.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Ocupational Therapy (COT)
Description: Conventional occupational therapy pertaining to hand function represents control activities against which the FES therapy was assessed. The conventional occupational therapy included: a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; b) task-specific, repetitive functional training; c) strengthening and motor control training using resistance to available arm motion to increase strength; d) stretching exercises; e) electrical stimulation applied primarily for muscle strengthening (this is not FES but TENS application); f) activities of daily living including self-care where the upper limb was used as an assist if appropriate; and g) caregiver training.
Study: NCT03798353

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix.
Description: A matrix-cell construct (PeriCord) will be placed on the ischemic area of the non-candidate revascularization area during a surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery by sternotomy
Description: The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed only the by-pass.
Study: NCT03241719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Subjects will receive vascularized composite allotransplantation (e.g. facial, hand and/or abdominal wall transplants) under conventional immune suppression. No sooner than 3 months after VCA, subjects will receive a protocol of daily recombinant IL-2 at low doses for 8 weeks.
Study: NCT02281383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG)
Study: NCT02172690

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Staging
Description: Laparoscopic Staging
Study: NCT02223494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbogrel
Study: NCT01025518

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance training
Description: 12 weeks of resistance training in combination with protein and creatine or placebo ingestion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: 12 weeks of resistance training in combination with protein and creatine or placebo ingestion

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein and creatine
Description: 30 g of protein with each training session, 5 g of creatine pr day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrine
Study: NCT01119209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Approved by the Danish Medicines Agency

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Approved by the Danish Medicines Agency

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Approved by the Danish Medicines Agency
Study: NCT01169818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous~Dose regimen: initial: once a day in the evening at bedtime. Titration will occur each time the middle FPG (Fasting Plasma Glucose) value is above target

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous~Dose regimen: initial: once a day in the evening at bedtime. Titration will occur each time the middle FPG (Fasting Plasma Glucose) value is above target
Study: NCT00515268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256066
Description: GSK256066 will be available as dry powder inhaler with dosing strengths of 12.5, 37.5, 50 micrograms per inhalation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo inhaler.
Study: NCT03822559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL
Description: One drop a time, once daily administration of DE-111A eye drops in the affected eye(s) at 8:00 am (±1h) for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL
Description: One drop a time, once daily administration of preservative-free 0.0015% tafluprost eye drops in the affected eye(s) at 8:00 (±1h) for 3 months.
Study: NCT02038361

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: blood draw
Study: NCT04245683

Intervention type: PROCEDURE
Intervention: Bowel/rectal resection
Description: surgical removal of the portion of the rectum where the tumor was originally identified

Intervention type: OTHER
Intervention: non-operative follow up
Description: patients who choose the non-operative option will be required to adhere to a very intensive follow up protocol, including endoscopy and CT imaging
Study: NCT00684541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpretation Modification Program
Description: The IMP protocol includes twelve 30-min sessions delivered over a 6-week period. Each session will comprise 220 trials. In each trial, participants will first see either a non-threat or a threat (e.g. graceful or clumsy) word on the computer screen. They will then see an ambiguous sentence (e.g. You dance at the party) and will be asked to indicate if the word and sentence were related by pressing a corresponding key. Participants will receive positive feedback (i.e., You are correct!) when they endorse a non-threat interpretation or reject a threat interpretation of an ambiguous sentence. Participants will receive negative feedback (i.e., You are incorrect.) when they endorse a threat interpretation or reject a non-threat interpretation of an ambiguous sentence.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Interpretation Control Condition
Description: Participants assigned to the PC completed an identical procedure to the IMP procedure except that feedback about participants' performance was not contingent on the type of interpretation (i.e., non-threat or threat) endorsed. Thus, participants in the PC received positive feedback 50% of the time when viewing a threat interpretation and 50% of the time when viewing a non-threat interpretation.
Study: NCT04664699

Intervention type: DEVICE
Group type: OTHER
Intervention: Plethymographic Variability Index
Description: All patients were monitored with the electrocardiogram (ECG), Non Invasive Blood Pressure (NIBP), Pulse oximetry (SpO2) and invasively with an arterial line and central venous line as per institutional protocol. In the PVI group, a pulse oximetry probe was connected to the fourth finger of the hand that did not have an arterial cannulation. The pulse oximeter was connected to a monitor The Massimo ® pulse oximeter (Massimo Corp., Irvine, CA, USA), which has a module for PVI measurements.~PVI ≥13% indicates volume responsiveness, and PVI \< 13% indicates adequate volume

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard Monitoring
Description: All patients were monitored with the electrocardiogram (ECG), Non Invasive Blood Pressure (NIBP), Pulse oximetry (SpO2) and invasively with an arterial line and central venous line as per institutional protocol. Patients were resuscitated according to mean arterial pressure/ heart rate and urine output.
Study: NCT03103477

Intervention type: OTHER
Intervention: Urine stability
Description: This study is proposing to assess PAF and PAF-AH activity in urine after using various handling methods of the urine specimen. Better understanding of PAF stability will allow for better design of future experiments involving PAF in interstitial cystitis patients.

Intervention type: OTHER
Intervention: Urine stability
Description: This study is proposing to assess PAF and PAF-AH activity in urine after using various handling methods of the urine specimen. Better understanding of PAF stability will allow for better design of future experiments involving PAF in interstitial cystitis patients.
Study: NCT00282308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab was supplied in single-use vials.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisone
Description: Patients received methylprednisolone 100 mg intravenously before each infusion of rituximab.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: C. albicans
Description: Patients received an intradermal injection of C. albicans (0.1 mL) on the volar surface of the forearm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. albicans
Description: Patients received an intradermal injection of C. albicans (0.1 mL) on the volar surface of the forearm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus toxoid adsorbed booster vaccine
Description: Patients received an intramuscular injection of the tetanus toxoid adsorbed booster vaccine (1 mg in 0.5 mL) in the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid adsorbed booster vaccine
Description: Patients received an intramuscular injection of the tetanus toxoid adsorbed booster vaccine (1 mg in 0.5 mL) in the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: Patients received an intramuscular injection of the 23-valent pneumococcal polysaccharide vaccine (0.5 mL) in the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: Patients received an intramuscular injection of the 23-valent pneumococcal polysaccharide vaccine (0.5 mL) in the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Keyhole limpet hemocyanin
Description: Patients received a subcutaneous injection of keyhole limpet hemocyanin (1 mg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Keyhole limpet hemocyanin
Description: Patients received a subcutaneous injection of keyhole limpet hemocyanin (1 mg)